Abstract
BackgroundPrevious studies had shown that microRNA-638 (miR-638) exhibited different effects in malignant tumors. Moreover, the function of miR-638 has not been reported in breast cancer. Hence, we designed this research to explore the function of miR-638 in breast cancer.MethodsFirstly, miR-638 expressions were measured in breast cancer tissues via RT-qPCR. Protein expressions were detected through immunocytochemical (IHC) assay and western blot analysis. Then, Cell Counting Kit-8 (CCK-8) assay and Transwell assay were conducted to observe proliferation and motility of the cells. Dual luciferase assay was performed to confirm the binding site between miR-638 and Homeobox protein Hox-A9 (HOXA9).ResultsReduced expression of miR-638 was detected in breast cancer. And low miR-638 expression was related to poor prognosis in patients with breast cancer. Functionally, the viability, migration, and invasion of the breast cancer cells were suppressed by miR-638 overexpression. Furthermore, miR-638 can directly bind to HOXA9, and increased expression of HOXA9 was also detected in breast cancer. In particular, HOXA9 upregulation can impair anti-tumor effect of miR-638 in breast cancer, and miR-638 can hinder the Wnt/β-cadherin pathway and epithelial-mesenchymal transition (EMT) in breast cancer.ConclusionmiR-638 inhibits breast cancer progression through binding to HOXA9.
Highlights
Breast cancer usually occurs in the epithelium of the breast gland that seriously endangers women’s lives [1]
Results miR-638 expression was decreased in breast cancer tissues Firstly, miR-638 expressions were observed in breast cancer tissues
The results suggested that abnormal miR-638 expression was related to the tumorigenesis and prognosis of breast cancer
Summary
Breast cancer usually occurs in the epithelium of the breast gland that seriously endangers women’s lives [1]. Breast cancer usually occurs in women, and only about 1-2% of the patients with breast cancer are men [2]. MiR-384 was found to inhibit breast cancer progression by targeting ACVR1 [8]. MiR-374a promoted tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer [9]. Previous studies showed that miR-638 was an important regulator for the occurrence and development of human cancers. MiR-638 can predict the outcome of the patients with non-small cell lung cancer after chemotherapy [13]. Zhao et al found that potentiation of docetaxel sensitivity was regulated by miR-638 via regulation of STARD10 pathway in human breast cancer cells [14]. The function of miR-638 has not been reported in breast cancer. We designed this research to explore the function of miR-638 in breast cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
